0.3322
2.29%
-0.0078
After Hours:
.3473
0.0151
+4.55%
Apollomics Inc stock is currently priced at $0.3322, with a 24-hour trading volume of 105.39K.
It has seen a -2.29% decreased in the last 24 hours and a -37.32% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.3364 pivot point. If it approaches the $0.3236 support level, significant changes may occur.
Previous Close:
$0.34
Open:
$0.351
24h Volume:
105.39K
Market Cap:
$29.73M
Revenue:
-
Net Income/Loss:
$-172.60M
P/E Ratio:
-0.0629
EPS:
-5.2851
Net Cash Flow:
$-43.22M
1W Performance:
-10.67%
1M Performance:
-37.32%
6M Performance:
-56.29%
1Y Performance:
-92.27%
Apollomics Inc Stock (APLM) Company Profile
Name
Apollomics Inc
Sector
Industry
Phone
650 209 4055
Address
989 East Hillsdale Blvd, Suite 220, Foster City
Apollomics Inc Stock (APLM) Latest News
HC Wainwright Lowers Apollomics (NASDAQ:APLM) Price Target to $2.00 - Defense World
Defense World
Apollomics shares target cut on Phase 3 study results - Investing.com
Investing.com
Apollomics Announces Private Placement Financing and Addition to Board of Directors - GlobeNewswire
GlobeNewswire
Apollomics shares target cut on Phase 3 study results By Investing.com - Investing.com
Investing.com
Ratio Examination: Apollomics Inc (APLM)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
The Dwinnex
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET - EIN News
EIN News
Apollomics Inc Stock (APLM) Financials Data
Apollomics Inc (APLM) Net Income 2024
APLM net income (TTM) was -$172.60 million for the quarter ending December 31, 2023, a -82.07% decrease year-over-year.
Apollomics Inc (APLM) Cash Flow 2024
APLM recorded a free cash flow (TTM) of -$43.22 million for the quarter ending December 31, 2023, a +15.03% increase year-over-year.
Apollomics Inc (APLM) Earnings per Share 2024
APLM earnings per share (TTM) was -$2.32 for the quarter ending December 31, 2023, a -112.42% decline year-over-year.
About Apollomics Inc
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Cap:
|
Volume (24h):